CORRECTION – Cortex Business Solutions Announces Q3

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
215
CORRECTION – Cortex Business Solutions Announces Q3 Fiscal 2018 Financial Results

CALGARY, Alberta, June 12, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cortex Business Solutions Inc. (TSXV:CBX), we are advised by the company there have been numerous changes to figures in the financial tables. Complete corrected text follows.

Cortex Business Solutions Announces Q3 Fiscal 2018 Financial Results

Record Adjusted EBITDA (1) and cash flows from operations supported by 15% YOY revenue growth

CALGARY, Alberta, June 12, 2018 (GLOBE NEWSWIRE) -- Cortex Business Solutions Inc. (“Cortex”) (TSXV:CBX), a North American network-as-a-service e-invoicing solutions provider, today announces its three and nine months ended April 30, 2018 (“Q3 F2018”) Management’s Discussion and Analysis and Consolidated Financial Statements. 

“I believe these results are just the beginning of the momentum that we are building at Cortex. Our team has remained focused on helping our customers to deliver their own results and savings with our ever-expanding service. We have never helped as many suppliers get paid as quickly as we have in this past quarter and our recently released payments business is now one of the fastest growing income lines at Cortex. I could not be more excited with the trajectory that Cortex is on,” said Joel Leetzow, President and CEO of Cortex Business Solutions.

“Cortex was successful in growing its recurring access revenue YTD by 26% and overall YTD revenue by 15% compared to prior year. Along with another quarter of record adjusted EBITDA, these results and the large cash balance will allow Cortex to explore further growth through M&A and developing new products internally,” said Jason Baird, VP, Finance & CFO of Cortex Business Solutions. “I believe Fiscal 2018 results has confirmed that Cortex is on the right path to achieving its long-term growth strategy.”

Q3 F2018 Financial Highlights

Three months ended April 30, 2018 compared to April 30, 2017

  • Adjusted EBITDA (1)  increased 264% or by $0.4 million to $0.6 million from $0.2 million
  • Positive cash flow from operating activities increased 249% to $0.8 million from positive cash flows from operating activities of $0.2 million
  • Overall revenue increased 6% or by $0.2 million to $3.1 million from $2.9 million
  • Access and usage fees increased 12% or by $0.3 million to $2.9 million from $2.6 million
  • Gross profit improved 11% or by $0.2 million to $2.3 million from $2.1 million
  • Net income improved 3,147% or by $0.6 million to $0.6 million from $0.02 million

Nine months ended April 30, 2018 compared to April 30, 2017

  • Adjusted EBITDA (1)  increased 358% or by $1.3 million to $1.7 million from $0.4 million
  • Positive cash flow from operating activities increased materially to $1.3 million from positive cash flows from operating activities of $0.006 million
  • Overall revenue increased 15% or by $1.3 million to $9.4 million from $8.1 million
  • Access and usage fees increased 17% or by $1.2 million to $8.6 million from $7.3 million
  • Access fees increased 26% to $5.6 million from $4.4 million
  • Gross profit improved 24% or by $1.2 million to $6.9 million from $5.7 million
  • Net income improved 565% or by $1.6 million to $1.3 million from $(0.3) million

Cash Position

The overall cash position of Cortex improved 21% to $7.6 million at April 30, 2018, 2018 from $6.2 million at July 31, 2017 driven predominantly from an increase in net cash provided by operating activities mainly from higher access and usage fees and project management revenues. 

(1)  Adjusted EBITDA is defined as earnings before interest, taxes, depreciation and amortization, non-recurring charges and share based payments. Adjusted EBITDA is a non-IFRS financial measure that does not have any standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other reporting issuers. This measure assists the Company in evaluating the Company’s operating performance against its expectations and against other entities. Please refer to the Company’s management’s discussion and analysis for the quarter ended January 31, 2018 for further information on the Company’s use of Adjusted EBITDA and a reconciliation of Adjusted EBITDA to Net Income.

Cortex’s management will host a conference call, followed by a question and answer period. 

The details of the conference call are as follows:

Date:           Wednesday, June 13, 2018
Time:         10:00 a.m. Eastern time (8:00 a.m. Mountain time) 
Toll-free dial-in number:       1-800-273-9672
International dial-in number:     1-416-340-2216
     

Please call the conference telephone number ten minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Cortex Business Solutions at 403 219-2838.

A replay of the conference call will be available after the call through June 20, 2018.

Toll-free replay number:         1-800-408-3053                                                
Toll replay number:       1-905-694-9451   
Replay ID:         1177420#   
       

About Cortex

Cortex’s strategy is to revolutionize B2B document exchange by replacing traditional paper-based manual systems with automated e-invoicing. This positions companies with the scalability and flexibility needed to meet the demands of today’s business. Cortex offers a B2B network that enables electronic invoicing for buying and supplying organizations using flexible connection methods to leverage existing customer technologies and processes. Access to the Cortex Network enhances the exchange of documents allowing companies to connect and interact with each other to grow their businesses.

Cortex is currently delivering e-invoicing services to over 10,000 Trading Partners in Oil & Gas, Mining, Manufacturing and Sports & Entertainment industries, with a focused expansion into additional verticals.

For more information, please visit www.cortex.net .

Investor Relations Contacts:

Joel Leetzow                President and CEO          jleetzow@cortex.net      403-219-2838                      Jason Baird          VP, Finance & CFO     jbaird@cortex.net 403-219-2838    

Cortex Business Solutions Inc. Condensed Consolidated Interim Statements of Financial Position

(Prepared in Canadian Dollars) (Unaudited)

    April 30 2018   July 31 2017
Assets        
         
Current Assets        
Cash and cash equivalents   $ 7,561,299     $ 6,248,176  
Short-term investments     60,000       60,000  
Accounts receivable   1,092,404       1,220,442  
Prepaid expenses     218,281       180,710  
         
      8,931,984       7,709,328  
         
Long-term receivable     112,083       98,761  
Deposits     67,439       35,061  
Property and equipment     112,428       178,118  
Intangible assets     23,264       30,018  
         
    $ 9,247,198     $ 8,051,286  
Liabilities        
         
Current Liabilities        
Accounts payable and accrued liabilities $ 1,125,052     $ 1,834,471  
Deferred revenue     375,919       423,734  
Current income tax payable   20,951       9,203  
Current portion of obligations under finance  lease   22,923       -  
         
      1,515,183       2,267,408  
Deferred rent     150,445       -  
Obligations under finance lease   19,511       -  
         
      1,714,801       2,267,408  
Shareholders' Equity        
         
Share capital     60,771,418       60,562,286  
Accumulated other comprehensive income   602,103       591,752  
Contributed surplus     9,802,315       9,526,341  
Deficit     (63,643,439 )     (64,896,501 )
         
      7,532,397       5,783,878  
         
    $ 9,247,198     $ 8,051,286  
 
 

Cortex Business Solutions Inc. Condensed Consolidated Interim Statement of Income (Loss) and Comprehensive Income (Loss) For the three and nine months ended April 30, 2018 and 2017 (Prepared in Canadian Dollars) (Unaudited)

    Three months ended April 30   Nine months ended April 30
      2018       2017       2018       2017  
Revenue                
Access and usage fees   $ 2,911,847     $ 2,603,932     $ 8,575,652     $ 7,339,745  
Integration fees     87,612       119,792       224,856       220,391  
Project management and other revenue   113,384       207,002       565,963       561,334  
                 
      3,112,843       2,930,726       9,366,471       8,121,470  
                 
Cost of Sales     808,897       853,057       2,430,701       2,449,037  
                 
Gross Profit     2,303,946       2,077,669       6,935,770       5,672,433  
                 
Expenses                
Sales and marketing     501,039       596,473       1,675,601       1,640,534  
Research and development     479,843       500,338       1,416,573       1,403,028  
General and administrative     709,182       908,697       2,478,327       2,725,034  
Severance and termination     5,747       36,436       164,431       128,057  
                 
      1,695,811       2,041,944       5,734,932       5,896,653  
                 
Income (loss) before finance income   608,135       35,725       1,200,838       (224,220 )
                 
Finance income     38,540       921       58,701       1,359  
                 
Income tax expense     (2,227 )     (16,799 )     (6,477 )     (46,464 )
                 
Net income (loss)   $ 644,448     $ 19,847     $ 1,253,062     $ (269,325 )
                 
                 
Other comprehensive earnings                
Items that may be reclassified subsequently to net income (loss):        
                 
Foreign exchange gain on foreign operations     60,197         97,922         10,351       70,473  
                 
Comprehensive income (loss)   $ 704,645     $ 117,769     $ 1,263,413     $ (198,852 )
                 
Net income (loss) per share – basic and diluted $ 0.07     $ 0.00     $ 0.14     $ (0.03 )
 
 

Cortex Business Solutions Inc. Condensed Consolidated Interim Statement of Changes in Shareholders’ Equity (Prepared in Canadian Dollars) (Unaudited)           

  Number of Common Shares     Share Capital     Accumulated Other Comprehensive Income     Contributed Surplus     Deficit         Total Shareholders’ Equity
             
Balance – July 31, 2016 8,984,704     $ 60,291,515   $ 640,232     $ 9,126,948       $ (64,481,187 )   $ 5,577,508  
             
Net loss -     -     -       -       (269,325 )     (269,325 )
Translation of foreign operations -     -     70,473       -       -       70,473  
Compensation units & stock options exercised 6,158     26,491      -       (14,442 )      -       12,049  
Deferred share units issued -     -     -       200,000       -       200,000  
Stock based compensation -     -     -       219,361       -       219,361  
             
Balance – April 30, 2017 8,990,862     60,318,006     710,705       9,531,867       (64,750,512 )     5,810,066  
             
Balance - July 31, 2017 9,069,983     60,562,286     591,752       9,526,341       (64,896,501 )     5,783,878  
             
Net income -     -     -       -       1,253,062       1,253,062  
Translation of foreign operations -     -     10,351       -       -       10,351  
Compensation units & stock options exercised 27,163      89,132       -         (31,051 )       -        58,081  
Deferred share units exercised for shares 40,554     120,000      -       (120,000 )      -        -  
Deferred share units issued -     -     -       200,000       -       200,000  
Stock based compensation -     -     -       227,025       -       227,025  
             
Balance – April 30, 2018 9,137,700   $ 60,771,418   $ 602,103     $ 9,802,315     $ (63,643,439 )   $ 7,532,397  
 
 

Cortex Business Solutions Inc. Condensed Consolidated Interim Statement of Cash Flows For the three and nine months ended April 30, 2018 and 2017 (Prepared in Canadian Dollars) (unaudited)

  Three months ended April 30   Nine months ended April 30
   2018    2017   2018    2017
Cash provided by (used in)              
               
Operating activities              
Net income (loss) $ 644,448     $ 19,847     $ 1,253,062     $ (269,325 )
Items not affecting cash              
Stock-based compensation   78,627       67,740       427,025       419,361  
Amortization   9,220       25,004       167,681       74,889  
Deferred Rent   (9,400 )     -       150,445       -  
Accretion on rebate provision   -       2,153       -       6,460  
Loss on disposal of equipment   868       -       868       1,012  
Long term receivables   21,963       (26,517 )     (13,322 )     (79,551 )
Changes in non-cash working capital   97,323       153,229       (687,393 )     (146,393 )
               
Net cash provided by operating activities   843,049       241,456       1,298,366       6,453  
               
Financing activities              
Proceeds on exercise of compensation units & stock options    -       5,067        58,081       12,049  
Finance lease payments   (5,696 )     -       (24,371 )     -  
               
Net cash provided by (used in) financing activities   (5,696 )     5,067         33,710       12,049  
               
Investing Activities              
Acquisition of property and equipment   (11,591 )     (548 )     (29,300 )     (2,888 )
               
Net cash used in investing activities   (11,591 )     (548 )     (29,300 )     (2,888 )
               
     
Effect of exchange rate changes on cash and cash    equivalents held in foreign currency   60,197        97,822         10,347       70,472  
               
Cash inflow   885,959       343,797       1,313,123       86,086  
               
Cash, beginning of period   6,675,340       5,574,766       6,248,176       5,621,835  
               
Cash, end of period $ 7,561,299     $ 5,918,563     $ 7,561,299     $ 5,707,921  
Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading

Top 5 Most Recently Viewed Articles

Man Group PLC Highlights Its Strategic Disclosures on Tritax REIT

Updated Category News Views 148

Strategic Position Disclosure by Man Group PLC Man Group PLC is actively sharing its significant interests in the securities market, particularly focusing on its involvement with Tritax Big Box REIT plc. As a key player in the investment landscape, this disclosure marks an important step for the company regarding its strategic holdings. Key Information Pertaining to the...

Continue Reading
TalentLMS and Epignosis Lead the Way in GDPR Compliance

Updated Category News Views 720

TalentLMS and Epignosis Set the Standard for GDPR Compliance TalentLMS, along with its parent company Epignosis, has continuously led the way in providing a fully compliant Learning Management System (LMS) with regards to the General Data Protection Regulation (GDPR). Recent developments affirm that TalentLMS remains the only LMS globally to uphold its commitment to this...

Continue Reading
Zillow and Esusu Forge New Path to Boost Renters' Credit Scores

Updated Category News Views 283

Building Credit for Renters with Zillow and Esusu The recent collaboration between Zillow and Esusu marks a significant step towards empowering renters across the country to build their credit. This partnership allows any renter to report their on-time rent payments, significantly enhancing their credit profiles, for just $20 a year. How the Partnership Works Starting...

Continue Reading
iCrowdNewswire Leverages DeepL for Enhanced Global Communication

Updated Category News Views 121

iCrowdNewswire Enhances Multilingual Capabilities iCrowdNewswire, a prominent international press release distribution company, has embarked on a transformative journey to improve its multilingual services through the introduction of the DeepL API. The integration of DeepL's cutting-edge language AI technology has significantly boosted iCrowdNewswire’s ability to...

Continue Reading
Celebrating Excellence: Top Surgeons Recognized in Endocrine Care

Updated Category News Views 82

Exceptional Recognition for Leading Surgeons in Endocrine Surgery Dr. Jim Norman and Dr. Gary Clayman Acknowledged as Premier Specialists The Hospital for Endocrine Surgery is proud to announce that two of its distinguished surgeons, Dr. Jim Norman and Dr. Gary Clayman, have been honored in the prestigious Castle Connolly Top Doctors list for 2025. This remarkable...

Continue Reading